LETTER TO THE EDITOR

Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes

Bisoprolol, a Biopharmaceutics Classification System (BCS) class 1 drug, exhibits a prolonged time to maximum concentration (Tmax) after an oral solution administration, challenging mechanistic bisoprolol pharmacokinetic simulations. As noted by Dr. Macwan, there are three bisoprolol physiologically-based pharmacokinetic (PBPK) models attempted to simulate the delayed Tmax in dissimilar manners, the first one with a modified gastric emptying time of 0.6 h by us, the second one with a “worst-case” scenario intestinal permeability for BCS class 1 drugs of $1.1 \times 10^{-4}$ cm/s, and the third one by Macwan et al. with a fitted fraction unbound in enterocytes (fu_{int}) of 5% to account for lysosomal trapping in enterocytes. Dr. Macwan et al. believe strongly that their model with lysosomal trapping is the most probable.

At that point, the first bisoprolol PBPK model was developed a decade ago, little information concerning the impact of lysosomal trapping on oral drug absorption was available. To our knowledge, lysosomal trapping in enterocytes was incorporated into PBPK modeling for the first time in 2017. Hence, we had to consider any alternative mechanisms probably causing prolonged Tmax when we developed the first bisoprolol PBPK model. Given large variability in gastric emptying time (0.25 h and 0.4 h implemented in Gastroplus and Simcyp, respectively) and a phenomenon of drug-induced gastric emptying prolongation, we decided to modify the Gastroplus default value of stomach transit time to reproduce the delayed Tmax without compromising maximum plasma concentration (Cmax). Indeed, we were aware of a couple of shortcomings by modifying the value. First, it might be difficult to translate bisoprolol pharmacokinetics from healthy subjects to a specific population when the intended population shows an impaired or accelerated gastric emptying. Second, drug-induced gastric emptying prolongation for bisoprolol has neither been determined nor excluded.

Regarding lysosomal trapping on distribution, we have to clarify that we had already considered by fitting in silico blood-to-plasma ratio of ~0.85 to 1.1 to simulate elevated volume of distribution at steady state (Vss) owing to lysosomal trapping in tissues.

Overall, although we are persuaded by Macwan that their model is, thus far, the most mechanistic one by accounting for lysosomal trapping in enterocytes, we believe PBPK models should be viewed as knowledge-driven models, which could evolve when new knowledge/information of either systems physiology or drug-specific mechanisms becomes increasingly available. Based upon current knowledge, we agree, for highly permeable, lipophilic, week base compounds showing an unexpectedly long Tmax who are similar structurally to those demonstrated to undergo lysosomal sequestration, lysosomal trapping in enterocytes should be considered in mechanistic absorption modeling.

FUNDING INFORMATION

G.Y. was supported by Jiangsu Provincial Natural Science Fund for Distinguished Young Scholars (BK20200005). The funding organization played no role in the preparation, review, or approval of the manuscript.

CONFLICT OF INTEREST

The authors declared no competing interests for this work.

Dan-Na Wu
Guo Yu
Guo-Fu Li

1Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Hainan, China
2Clinical Medical College, Yangzhou University, Yangzhou, China

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Correspondence
Guo-Fu Li, Subei People’s Hospital, Yangzhou 225009, China.
Email: guofu.g.li@gmail.com

ORCID
Guo Yu https://orcid.org/0000-0001-6685-2167
Guo-Fu Li https://orcid.org/0000-0002-4628-9941

REFERENCES
1. Macwan JS, Fraczkiewicz G, Bertolino M, Krüger P, Peters SA. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: the case of bisoprolol. CPT Pharmacometrics Syst Pharmacol. 2021;10(6):622-632.
2. Li GF, Wang K, Chen R, Zhao HR, Yang J, Zheng QS. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin. 2012;33(11):1359-1371.
3. Hansmann S, Darwich A, Margolskee A, Aarons L, Dressman J. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. J Pharm Pharmacol. 2016;68(12):1501-1515.
4. Samant TS, Lukacova V, Schmidt S. Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: a desipramine case study. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):315-321.
5. Peters SA, Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn. 2008;35(1):1-30.